Global Gout Drugs research

Gout Drugs Comprehensive Study by Type (Colchicine, Antihyperuricemic Agents (Urate-Lowering Drugs), Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Others), Application (Clinic, Hospital, Residential), Distribution Channel (Hospital Pharmacy, Online Sales, Retail Pharmacy), Disease Condition (Acute Gout, Chronic Gout) Players and Region - Global Market Outlook to 2029

Gout Drugs Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
A Gout is a form of Provocative arthritis which are identified by frequent attacks of severing high-level pain and maybe swollen joints. Hence it is a necessity to identify these diseases and to provide the drugs related to these diseases. The global market for these drugs is anticipated to grow in the foreseen market, owing to the reasons for major drug pipelines, changing lifestyle and many more. Therefore, increasing the market scope of these drugs to widen its areas across the Globe.

The Global Gout Drugs market presents a comprehensive analysis of the Gout Drugs market by product type (Colchicine, Antihyperuricemic Agents (Urate-Lowering Drugs), Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids and Others), by end-user/application (Clinic, Hospital and Residential), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. The key Players profiled in the report are Sun Pharma (India), Mylan (United States), Apotex (Canda), Synpac-Kingdom (Taiwan), Yunnan Phytopharmaceutical (China), AstraZeneca (United Kingdom), Horizon Pharma plc (Ireland), Takeda Pharmaceutical Company Limited (Japan), GlaxoSmithKline plc (United Kingdom) and Novartis AG (Switzerland). Additionally, other players that are part of this comprehensive study are Merck & Co. Inc. (United States) and Teijin Pharma Limited (Japan).

AttributesDetails
Study Period2019-2029
Base Year2023
Forecast Period2022-2029
Historical Period2019-2023
UnitValue (USD Million)
Key Companies ProfiledSun Pharma (India), Mylan (United States), Apotex (Canda), Synpac-Kingdom (Taiwan), Yunnan Phytopharmaceutical (China), AstraZeneca (United Kingdom), Horizon Pharma plc (Ireland), Takeda Pharmaceutical Company Limited (Japan), GlaxoSmithKline plc (United Kingdom) and Novartis AG (Switzerland)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Asia-Pacific is the Trending Market for this Drugs or Therapeutics, Likely Owing to Account for a Significant Share of the Global Gout Therapeutics Market by 2027 and Rising Adoption of Biologics and Increasing R&D on Regenerative Medicines

Market Growth Drivers:
Constant Problems of Arthritis is one of the Major Factors and Increasing Prevalence’s of Many Chronic Diseases

Challenges:
Counterfeit of these Drugs is Hampering the Market, Side Effects of Gout Therapeutic Drugs and High Indirect Costs of Gout Therapeutics

Restraints:
Strict Regulations of Various Drugs may Hinder the Gout Drug Market and Concern Related Towards the Patent Expiry of these Drugs

Opportunities:
The Rise in the Demand for Biologics for Gout Treatments and The Rapid Increase in the Geriatric Population is Boosting the Market

Regional Breakdown and Segment Analysis
This section of our report presents a realistic picture of the Global Gout Drugs industry. Investors and manufacturers can easily understand the inherent opportunities and challenges for their products in the geographical region of interest.

The Distribution Channel, such as Hospital Pharmacy, is boosting the Gout Drugs market and is anticipated to experience a steady growth during the forecast period.

The Disease Condition, such as Acute Gout, is boosting the Gout Drugs market and is anticipated to experience a steady growth during the forecast period.

The regional segmentation covered in this report are:
South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)

Report Objectives / Segmentation Covered

By Type
  • Colchicine
  • Antihyperuricemic Agents (Urate-Lowering Drugs)
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Others
By Application
  • Clinic
  • Hospital
  • Residential
By Distribution Channel
  • Hospital Pharmacy
  • Online Sales
  • Retail Pharmacy

By Disease Condition
  • Acute Gout
  • Chronic Gout

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Constant Problems of Arthritis is one of the Major Factors
      • 3.2.2. Increasing Prevalence’s of Many Chronic Diseases
    • 3.3. Market Challenges
      • 3.3.1. Counterfeit of these Drugs is Hampering the Market
      • 3.3.2. Side Effects of Gout Therapeutic Drugs
      • 3.3.3. High Indirect Costs of Gout Therapeutics
    • 3.4. Market Trends
      • 3.4.1. Asia-Pacific is the Trending Market for this Drugs or Therapeutics, Likely Owing to Account for a Significant Share of the Global Gout Therapeutics Market by 2027
      • 3.4.2. Rising Adoption of Biologics and Increasing R&D on Regenerative Medicines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gout Drugs, by Type, Application, Distribution Channel, Disease Condition and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Gout Drugs (Value)
      • 5.2.1. Global Gout Drugs by: Type (Value)
        • 5.2.1.1. Colchicine
        • 5.2.1.2. Antihyperuricemic Agents (Urate-Lowering Drugs)
        • 5.2.1.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
        • 5.2.1.4. Corticosteroids
        • 5.2.1.5. Others
      • 5.2.2. Global Gout Drugs by: Application (Value)
        • 5.2.2.1. Clinic
        • 5.2.2.2. Hospital
        • 5.2.2.3. Residential
      • 5.2.3. Global Gout Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Online Sales
        • 5.2.3.3. Retail Pharmacy
      • 5.2.4. Global Gout Drugs by: Disease Condition (Value)
        • 5.2.4.1. Acute Gout
        • 5.2.4.2. Chronic Gout
      • 5.2.5. Global Gout Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Gout Drugs (Volume)
      • 5.3.1. Global Gout Drugs by: Type (Volume)
        • 5.3.1.1. Colchicine
        • 5.3.1.2. Antihyperuricemic Agents (Urate-Lowering Drugs)
        • 5.3.1.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
        • 5.3.1.4. Corticosteroids
        • 5.3.1.5. Others
      • 5.3.2. Global Gout Drugs by: Application (Volume)
        • 5.3.2.1. Clinic
        • 5.3.2.2. Hospital
        • 5.3.2.3. Residential
      • 5.3.3. Global Gout Drugs by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacy
        • 5.3.3.2. Online Sales
        • 5.3.3.3. Retail Pharmacy
      • 5.3.4. Global Gout Drugs by: Disease Condition (Volume)
        • 5.3.4.1. Acute Gout
        • 5.3.4.2. Chronic Gout
      • 5.3.5. Global Gout Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Gout Drugs (Price)
      • 5.4.1. Global Gout Drugs by: Type (Price)
  • 6. Gout Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sun Pharma (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Mylan (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Apotex (Canda)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Synpac-Kingdom (Taiwan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Yunnan Phytopharmaceutical (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Horizon Pharma plc (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gout Drugs Sale, by Type, Application, Distribution Channel, Disease Condition and Region (value, volume and price ) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Gout Drugs (Value)
      • 7.2.1. Global Gout Drugs by: Type (Value)
        • 7.2.1.1. Colchicine
        • 7.2.1.2. Antihyperuricemic Agents (Urate-Lowering Drugs)
        • 7.2.1.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
        • 7.2.1.4. Corticosteroids
        • 7.2.1.5. Others
      • 7.2.2. Global Gout Drugs by: Application (Value)
        • 7.2.2.1. Clinic
        • 7.2.2.2. Hospital
        • 7.2.2.3. Residential
      • 7.2.3. Global Gout Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Online Sales
        • 7.2.3.3. Retail Pharmacy
      • 7.2.4. Global Gout Drugs by: Disease Condition (Value)
        • 7.2.4.1. Acute Gout
        • 7.2.4.2. Chronic Gout
      • 7.2.5. Global Gout Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Gout Drugs (Volume)
      • 7.3.1. Global Gout Drugs by: Type (Volume)
        • 7.3.1.1. Colchicine
        • 7.3.1.2. Antihyperuricemic Agents (Urate-Lowering Drugs)
        • 7.3.1.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
        • 7.3.1.4. Corticosteroids
        • 7.3.1.5. Others
      • 7.3.2. Global Gout Drugs by: Application (Volume)
        • 7.3.2.1. Clinic
        • 7.3.2.2. Hospital
        • 7.3.2.3. Residential
      • 7.3.3. Global Gout Drugs by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacy
        • 7.3.3.2. Online Sales
        • 7.3.3.3. Retail Pharmacy
      • 7.3.4. Global Gout Drugs by: Disease Condition (Volume)
        • 7.3.4.1. Acute Gout
        • 7.3.4.2. Chronic Gout
      • 7.3.5. Global Gout Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Gout Drugs (Price)
      • 7.4.1. Global Gout Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gout Drugs: by Type(USD Million)
  • Table 2. Gout Drugs Colchicine , by Region USD Million (2018-2023)
  • Table 3. Gout Drugs Antihyperuricemic Agents (Urate-Lowering Drugs) , by Region USD Million (2018-2023)
  • Table 4. Gout Drugs Non-steroidal Anti-inflammatory Drugs (NSAIDs) , by Region USD Million (2018-2023)
  • Table 5. Gout Drugs Corticosteroids , by Region USD Million (2018-2023)
  • Table 6. Gout Drugs Others , by Region USD Million (2018-2023)
  • Table 7. Gout Drugs: by Application(USD Million)
  • Table 8. Gout Drugs Clinic , by Region USD Million (2018-2023)
  • Table 9. Gout Drugs Hospital , by Region USD Million (2018-2023)
  • Table 10. Gout Drugs Residential , by Region USD Million (2018-2023)
  • Table 11. Gout Drugs: by Distribution Channel(USD Million)
  • Table 12. Gout Drugs Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 13. Gout Drugs Online Sales , by Region USD Million (2018-2023)
  • Table 14. Gout Drugs Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 15. Gout Drugs: by Disease Condition(USD Million)
  • Table 16. Gout Drugs Acute Gout , by Region USD Million (2018-2023)
  • Table 17. Gout Drugs Chronic Gout , by Region USD Million (2018-2023)
  • Table 18. South America Gout Drugs, by Country USD Million (2018-2023)
  • Table 19. South America Gout Drugs, by Type USD Million (2018-2023)
  • Table 20. South America Gout Drugs, by Application USD Million (2018-2023)
  • Table 21. South America Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 22. South America Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 23. Brazil Gout Drugs, by Type USD Million (2018-2023)
  • Table 24. Brazil Gout Drugs, by Application USD Million (2018-2023)
  • Table 25. Brazil Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 26. Brazil Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 27. Argentina Gout Drugs, by Type USD Million (2018-2023)
  • Table 28. Argentina Gout Drugs, by Application USD Million (2018-2023)
  • Table 29. Argentina Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 30. Argentina Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 31. Rest of South America Gout Drugs, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Gout Drugs, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 34. Rest of South America Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 35. Asia Pacific Gout Drugs, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Gout Drugs, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Gout Drugs, by Application USD Million (2018-2023)
  • Table 38. Asia Pacific Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 39. Asia Pacific Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 40. China Gout Drugs, by Type USD Million (2018-2023)
  • Table 41. China Gout Drugs, by Application USD Million (2018-2023)
  • Table 42. China Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 43. China Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 44. Japan Gout Drugs, by Type USD Million (2018-2023)
  • Table 45. Japan Gout Drugs, by Application USD Million (2018-2023)
  • Table 46. Japan Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 47. Japan Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 48. India Gout Drugs, by Type USD Million (2018-2023)
  • Table 49. India Gout Drugs, by Application USD Million (2018-2023)
  • Table 50. India Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 51. India Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 52. South Korea Gout Drugs, by Type USD Million (2018-2023)
  • Table 53. South Korea Gout Drugs, by Application USD Million (2018-2023)
  • Table 54. South Korea Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 55. South Korea Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 56. Taiwan Gout Drugs, by Type USD Million (2018-2023)
  • Table 57. Taiwan Gout Drugs, by Application USD Million (2018-2023)
  • Table 58. Taiwan Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 59. Taiwan Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 60. Australia Gout Drugs, by Type USD Million (2018-2023)
  • Table 61. Australia Gout Drugs, by Application USD Million (2018-2023)
  • Table 62. Australia Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 63. Australia Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Gout Drugs, by Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Gout Drugs, by Application USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 68. Europe Gout Drugs, by Country USD Million (2018-2023)
  • Table 69. Europe Gout Drugs, by Type USD Million (2018-2023)
  • Table 70. Europe Gout Drugs, by Application USD Million (2018-2023)
  • Table 71. Europe Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 72. Europe Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 73. Germany Gout Drugs, by Type USD Million (2018-2023)
  • Table 74. Germany Gout Drugs, by Application USD Million (2018-2023)
  • Table 75. Germany Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 76. Germany Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 77. France Gout Drugs, by Type USD Million (2018-2023)
  • Table 78. France Gout Drugs, by Application USD Million (2018-2023)
  • Table 79. France Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 80. France Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 81. Italy Gout Drugs, by Type USD Million (2018-2023)
  • Table 82. Italy Gout Drugs, by Application USD Million (2018-2023)
  • Table 83. Italy Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 84. Italy Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 85. United Kingdom Gout Drugs, by Type USD Million (2018-2023)
  • Table 86. United Kingdom Gout Drugs, by Application USD Million (2018-2023)
  • Table 87. United Kingdom Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 88. United Kingdom Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 89. Netherlands Gout Drugs, by Type USD Million (2018-2023)
  • Table 90. Netherlands Gout Drugs, by Application USD Million (2018-2023)
  • Table 91. Netherlands Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 92. Netherlands Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 93. Rest of Europe Gout Drugs, by Type USD Million (2018-2023)
  • Table 94. Rest of Europe Gout Drugs, by Application USD Million (2018-2023)
  • Table 95. Rest of Europe Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 96. Rest of Europe Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 97. MEA Gout Drugs, by Country USD Million (2018-2023)
  • Table 98. MEA Gout Drugs, by Type USD Million (2018-2023)
  • Table 99. MEA Gout Drugs, by Application USD Million (2018-2023)
  • Table 100. MEA Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 101. MEA Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 102. Middle East Gout Drugs, by Type USD Million (2018-2023)
  • Table 103. Middle East Gout Drugs, by Application USD Million (2018-2023)
  • Table 104. Middle East Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 105. Middle East Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 106. Africa Gout Drugs, by Type USD Million (2018-2023)
  • Table 107. Africa Gout Drugs, by Application USD Million (2018-2023)
  • Table 108. Africa Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 109. Africa Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 110. North America Gout Drugs, by Country USD Million (2018-2023)
  • Table 111. North America Gout Drugs, by Type USD Million (2018-2023)
  • Table 112. North America Gout Drugs, by Application USD Million (2018-2023)
  • Table 113. North America Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 114. North America Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 115. United States Gout Drugs, by Type USD Million (2018-2023)
  • Table 116. United States Gout Drugs, by Application USD Million (2018-2023)
  • Table 117. United States Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 118. United States Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 119. Canada Gout Drugs, by Type USD Million (2018-2023)
  • Table 120. Canada Gout Drugs, by Application USD Million (2018-2023)
  • Table 121. Canada Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 122. Canada Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 123. Mexico Gout Drugs, by Type USD Million (2018-2023)
  • Table 124. Mexico Gout Drugs, by Application USD Million (2018-2023)
  • Table 125. Mexico Gout Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 126. Mexico Gout Drugs, by Disease Condition USD Million (2018-2023)
  • Table 127. Gout Drugs Sales: by Type(Unit)
  • Table 128. Gout Drugs Sales Colchicine , by Region Unit (2018-2023)
  • Table 129. Gout Drugs Sales Antihyperuricemic Agents (Urate-Lowering Drugs) , by Region Unit (2018-2023)
  • Table 130. Gout Drugs Sales Non-steroidal Anti-inflammatory Drugs (NSAIDs) , by Region Unit (2018-2023)
  • Table 131. Gout Drugs Sales Corticosteroids , by Region Unit (2018-2023)
  • Table 132. Gout Drugs Sales Others , by Region Unit (2018-2023)
  • Table 133. Gout Drugs Sales: by Application(Unit)
  • Table 134. Gout Drugs Sales Clinic , by Region Unit (2018-2023)
  • Table 135. Gout Drugs Sales Hospital , by Region Unit (2018-2023)
  • Table 136. Gout Drugs Sales Residential , by Region Unit (2018-2023)
  • Table 137. Gout Drugs Sales: by Distribution Channel(Unit)
  • Table 138. Gout Drugs Sales Hospital Pharmacy , by Region Unit (2018-2023)
  • Table 139. Gout Drugs Sales Online Sales , by Region Unit (2018-2023)
  • Table 140. Gout Drugs Sales Retail Pharmacy , by Region Unit (2018-2023)
  • Table 141. Gout Drugs Sales: by Disease Condition(Unit)
  • Table 142. Gout Drugs Sales Acute Gout , by Region Unit (2018-2023)
  • Table 143. Gout Drugs Sales Chronic Gout , by Region Unit (2018-2023)
  • Table 144. South America Gout Drugs Sales, by Country Unit (2018-2023)
  • Table 145. South America Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 146. South America Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 147. South America Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 148. South America Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 149. Brazil Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 150. Brazil Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 151. Brazil Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 152. Brazil Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 153. Argentina Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 154. Argentina Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 155. Argentina Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 156. Argentina Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 157. Rest of South America Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 158. Rest of South America Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 159. Rest of South America Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 160. Rest of South America Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 161. Asia Pacific Gout Drugs Sales, by Country Unit (2018-2023)
  • Table 162. Asia Pacific Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 163. Asia Pacific Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 164. Asia Pacific Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 165. Asia Pacific Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 166. China Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 167. China Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 168. China Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 169. China Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 170. Japan Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 171. Japan Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 172. Japan Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 173. Japan Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 174. India Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 175. India Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 176. India Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 177. India Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 178. South Korea Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 179. South Korea Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 180. South Korea Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 181. South Korea Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 182. Taiwan Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 183. Taiwan Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 184. Taiwan Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 185. Taiwan Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 186. Australia Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 187. Australia Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 188. Australia Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 189. Australia Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 190. Rest of Asia-Pacific Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 191. Rest of Asia-Pacific Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 192. Rest of Asia-Pacific Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 193. Rest of Asia-Pacific Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 194. Europe Gout Drugs Sales, by Country Unit (2018-2023)
  • Table 195. Europe Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 196. Europe Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 197. Europe Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 198. Europe Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 199. Germany Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 200. Germany Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 201. Germany Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 202. Germany Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 203. France Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 204. France Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 205. France Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 206. France Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 207. Italy Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 208. Italy Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 209. Italy Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 210. Italy Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 211. United Kingdom Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 212. United Kingdom Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 213. United Kingdom Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 214. United Kingdom Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 215. Netherlands Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 216. Netherlands Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 217. Netherlands Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 218. Netherlands Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 219. Rest of Europe Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 220. Rest of Europe Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 221. Rest of Europe Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 222. Rest of Europe Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 223. MEA Gout Drugs Sales, by Country Unit (2018-2023)
  • Table 224. MEA Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 225. MEA Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 226. MEA Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 227. MEA Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 228. Middle East Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 229. Middle East Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 230. Middle East Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 231. Middle East Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 232. Africa Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 233. Africa Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 234. Africa Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 235. Africa Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 236. North America Gout Drugs Sales, by Country Unit (2018-2023)
  • Table 237. North America Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 238. North America Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 239. North America Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 240. North America Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 241. United States Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 242. United States Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 243. United States Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 244. United States Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 245. Canada Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 246. Canada Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 247. Canada Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 248. Canada Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 249. Mexico Gout Drugs Sales, by Type Unit (2018-2023)
  • Table 250. Mexico Gout Drugs Sales, by Application Unit (2018-2023)
  • Table 251. Mexico Gout Drugs Sales, by Distribution Channel Unit (2018-2023)
  • Table 252. Mexico Gout Drugs Sales, by Disease Condition Unit (2018-2023)
  • Table 253. Gout Drugs: by Type(USD/Units)
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Gout Drugs: by Type(USD Million)
  • Table 265. Gout Drugs Colchicine , by Region USD Million (2024-2029)
  • Table 266. Gout Drugs Antihyperuricemic Agents (Urate-Lowering Drugs) , by Region USD Million (2024-2029)
  • Table 267. Gout Drugs Non-steroidal Anti-inflammatory Drugs (NSAIDs) , by Region USD Million (2024-2029)
  • Table 268. Gout Drugs Corticosteroids , by Region USD Million (2024-2029)
  • Table 269. Gout Drugs Others , by Region USD Million (2024-2029)
  • Table 270. Gout Drugs: by Application(USD Million)
  • Table 271. Gout Drugs Clinic , by Region USD Million (2024-2029)
  • Table 272. Gout Drugs Hospital , by Region USD Million (2024-2029)
  • Table 273. Gout Drugs Residential , by Region USD Million (2024-2029)
  • Table 274. Gout Drugs: by Distribution Channel(USD Million)
  • Table 275. Gout Drugs Hospital Pharmacy , by Region USD Million (2024-2029)
  • Table 276. Gout Drugs Online Sales , by Region USD Million (2024-2029)
  • Table 277. Gout Drugs Retail Pharmacy , by Region USD Million (2024-2029)
  • Table 278. Gout Drugs: by Disease Condition(USD Million)
  • Table 279. Gout Drugs Acute Gout , by Region USD Million (2024-2029)
  • Table 280. Gout Drugs Chronic Gout , by Region USD Million (2024-2029)
  • Table 281. South America Gout Drugs, by Country USD Million (2024-2029)
  • Table 282. South America Gout Drugs, by Type USD Million (2024-2029)
  • Table 283. South America Gout Drugs, by Application USD Million (2024-2029)
  • Table 284. South America Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 285. South America Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 286. Brazil Gout Drugs, by Type USD Million (2024-2029)
  • Table 287. Brazil Gout Drugs, by Application USD Million (2024-2029)
  • Table 288. Brazil Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 289. Brazil Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 290. Argentina Gout Drugs, by Type USD Million (2024-2029)
  • Table 291. Argentina Gout Drugs, by Application USD Million (2024-2029)
  • Table 292. Argentina Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 293. Argentina Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 294. Rest of South America Gout Drugs, by Type USD Million (2024-2029)
  • Table 295. Rest of South America Gout Drugs, by Application USD Million (2024-2029)
  • Table 296. Rest of South America Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 297. Rest of South America Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 298. Asia Pacific Gout Drugs, by Country USD Million (2024-2029)
  • Table 299. Asia Pacific Gout Drugs, by Type USD Million (2024-2029)
  • Table 300. Asia Pacific Gout Drugs, by Application USD Million (2024-2029)
  • Table 301. Asia Pacific Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 302. Asia Pacific Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 303. China Gout Drugs, by Type USD Million (2024-2029)
  • Table 304. China Gout Drugs, by Application USD Million (2024-2029)
  • Table 305. China Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 306. China Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 307. Japan Gout Drugs, by Type USD Million (2024-2029)
  • Table 308. Japan Gout Drugs, by Application USD Million (2024-2029)
  • Table 309. Japan Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 310. Japan Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 311. India Gout Drugs, by Type USD Million (2024-2029)
  • Table 312. India Gout Drugs, by Application USD Million (2024-2029)
  • Table 313. India Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 314. India Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 315. South Korea Gout Drugs, by Type USD Million (2024-2029)
  • Table 316. South Korea Gout Drugs, by Application USD Million (2024-2029)
  • Table 317. South Korea Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 318. South Korea Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 319. Taiwan Gout Drugs, by Type USD Million (2024-2029)
  • Table 320. Taiwan Gout Drugs, by Application USD Million (2024-2029)
  • Table 321. Taiwan Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 322. Taiwan Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 323. Australia Gout Drugs, by Type USD Million (2024-2029)
  • Table 324. Australia Gout Drugs, by Application USD Million (2024-2029)
  • Table 325. Australia Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 326. Australia Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 327. Rest of Asia-Pacific Gout Drugs, by Type USD Million (2024-2029)
  • Table 328. Rest of Asia-Pacific Gout Drugs, by Application USD Million (2024-2029)
  • Table 329. Rest of Asia-Pacific Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 330. Rest of Asia-Pacific Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 331. Europe Gout Drugs, by Country USD Million (2024-2029)
  • Table 332. Europe Gout Drugs, by Type USD Million (2024-2029)
  • Table 333. Europe Gout Drugs, by Application USD Million (2024-2029)
  • Table 334. Europe Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 335. Europe Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 336. Germany Gout Drugs, by Type USD Million (2024-2029)
  • Table 337. Germany Gout Drugs, by Application USD Million (2024-2029)
  • Table 338. Germany Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 339. Germany Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 340. France Gout Drugs, by Type USD Million (2024-2029)
  • Table 341. France Gout Drugs, by Application USD Million (2024-2029)
  • Table 342. France Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 343. France Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 344. Italy Gout Drugs, by Type USD Million (2024-2029)
  • Table 345. Italy Gout Drugs, by Application USD Million (2024-2029)
  • Table 346. Italy Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 347. Italy Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 348. United Kingdom Gout Drugs, by Type USD Million (2024-2029)
  • Table 349. United Kingdom Gout Drugs, by Application USD Million (2024-2029)
  • Table 350. United Kingdom Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 351. United Kingdom Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 352. Netherlands Gout Drugs, by Type USD Million (2024-2029)
  • Table 353. Netherlands Gout Drugs, by Application USD Million (2024-2029)
  • Table 354. Netherlands Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 355. Netherlands Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 356. Rest of Europe Gout Drugs, by Type USD Million (2024-2029)
  • Table 357. Rest of Europe Gout Drugs, by Application USD Million (2024-2029)
  • Table 358. Rest of Europe Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 359. Rest of Europe Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 360. MEA Gout Drugs, by Country USD Million (2024-2029)
  • Table 361. MEA Gout Drugs, by Type USD Million (2024-2029)
  • Table 362. MEA Gout Drugs, by Application USD Million (2024-2029)
  • Table 363. MEA Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 364. MEA Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 365. Middle East Gout Drugs, by Type USD Million (2024-2029)
  • Table 366. Middle East Gout Drugs, by Application USD Million (2024-2029)
  • Table 367. Middle East Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 368. Middle East Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 369. Africa Gout Drugs, by Type USD Million (2024-2029)
  • Table 370. Africa Gout Drugs, by Application USD Million (2024-2029)
  • Table 371. Africa Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 372. Africa Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 373. North America Gout Drugs, by Country USD Million (2024-2029)
  • Table 374. North America Gout Drugs, by Type USD Million (2024-2029)
  • Table 375. North America Gout Drugs, by Application USD Million (2024-2029)
  • Table 376. North America Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 377. North America Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 378. United States Gout Drugs, by Type USD Million (2024-2029)
  • Table 379. United States Gout Drugs, by Application USD Million (2024-2029)
  • Table 380. United States Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 381. United States Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 382. Canada Gout Drugs, by Type USD Million (2024-2029)
  • Table 383. Canada Gout Drugs, by Application USD Million (2024-2029)
  • Table 384. Canada Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 385. Canada Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 386. Mexico Gout Drugs, by Type USD Million (2024-2029)
  • Table 387. Mexico Gout Drugs, by Application USD Million (2024-2029)
  • Table 388. Mexico Gout Drugs, by Distribution Channel USD Million (2024-2029)
  • Table 389. Mexico Gout Drugs, by Disease Condition USD Million (2024-2029)
  • Table 390. Gout Drugs Sales: by Type(Unit)
  • Table 391. Gout Drugs Sales Colchicine , by Region Unit (2024-2029)
  • Table 392. Gout Drugs Sales Antihyperuricemic Agents (Urate-Lowering Drugs) , by Region Unit (2024-2029)
  • Table 393. Gout Drugs Sales Non-steroidal Anti-inflammatory Drugs (NSAIDs) , by Region Unit (2024-2029)
  • Table 394. Gout Drugs Sales Corticosteroids , by Region Unit (2024-2029)
  • Table 395. Gout Drugs Sales Others , by Region Unit (2024-2029)
  • Table 396. Gout Drugs Sales: by Application(Unit)
  • Table 397. Gout Drugs Sales Clinic , by Region Unit (2024-2029)
  • Table 398. Gout Drugs Sales Hospital , by Region Unit (2024-2029)
  • Table 399. Gout Drugs Sales Residential , by Region Unit (2024-2029)
  • Table 400. Gout Drugs Sales: by Distribution Channel(Unit)
  • Table 401. Gout Drugs Sales Hospital Pharmacy , by Region Unit (2024-2029)
  • Table 402. Gout Drugs Sales Online Sales , by Region Unit (2024-2029)
  • Table 403. Gout Drugs Sales Retail Pharmacy , by Region Unit (2024-2029)
  • Table 404. Gout Drugs Sales: by Disease Condition(Unit)
  • Table 405. Gout Drugs Sales Acute Gout , by Region Unit (2024-2029)
  • Table 406. Gout Drugs Sales Chronic Gout , by Region Unit (2024-2029)
  • Table 407. South America Gout Drugs Sales, by Country Unit (2024-2029)
  • Table 408. South America Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 409. South America Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 410. South America Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 411. South America Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 412. Brazil Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 413. Brazil Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 414. Brazil Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 415. Brazil Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 416. Argentina Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 417. Argentina Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 418. Argentina Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 419. Argentina Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 420. Rest of South America Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 421. Rest of South America Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 422. Rest of South America Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 423. Rest of South America Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 424. Asia Pacific Gout Drugs Sales, by Country Unit (2024-2029)
  • Table 425. Asia Pacific Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 426. Asia Pacific Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 427. Asia Pacific Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 428. Asia Pacific Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 429. China Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 430. China Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 431. China Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 432. China Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 433. Japan Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 434. Japan Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 435. Japan Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 436. Japan Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 437. India Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 438. India Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 439. India Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 440. India Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 441. South Korea Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 442. South Korea Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 443. South Korea Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 444. South Korea Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 445. Taiwan Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 446. Taiwan Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 447. Taiwan Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 448. Taiwan Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 449. Australia Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 450. Australia Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 451. Australia Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 452. Australia Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 453. Rest of Asia-Pacific Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 454. Rest of Asia-Pacific Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 455. Rest of Asia-Pacific Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 456. Rest of Asia-Pacific Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 457. Europe Gout Drugs Sales, by Country Unit (2024-2029)
  • Table 458. Europe Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 459. Europe Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 460. Europe Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 461. Europe Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 462. Germany Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 463. Germany Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 464. Germany Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 465. Germany Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 466. France Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 467. France Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 468. France Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 469. France Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 470. Italy Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 471. Italy Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 472. Italy Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 473. Italy Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 474. United Kingdom Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 475. United Kingdom Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 476. United Kingdom Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 477. United Kingdom Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 478. Netherlands Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 479. Netherlands Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 480. Netherlands Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 481. Netherlands Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 482. Rest of Europe Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 483. Rest of Europe Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 484. Rest of Europe Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 485. Rest of Europe Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 486. MEA Gout Drugs Sales, by Country Unit (2024-2029)
  • Table 487. MEA Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 488. MEA Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 489. MEA Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 490. MEA Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 491. Middle East Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 492. Middle East Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 493. Middle East Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 494. Middle East Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 495. Africa Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 496. Africa Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 497. Africa Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 498. Africa Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 499. North America Gout Drugs Sales, by Country Unit (2024-2029)
  • Table 500. North America Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 501. North America Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 502. North America Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 503. North America Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 504. United States Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 505. United States Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 506. United States Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 507. United States Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 508. Canada Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 509. Canada Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 510. Canada Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 511. Canada Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 512. Mexico Gout Drugs Sales, by Type Unit (2024-2029)
  • Table 513. Mexico Gout Drugs Sales, by Application Unit (2024-2029)
  • Table 514. Mexico Gout Drugs Sales, by Distribution Channel Unit (2024-2029)
  • Table 515. Mexico Gout Drugs Sales, by Disease Condition Unit (2024-2029)
  • Table 516. Gout Drugs: by Type(USD/Units)
  • Table 517. Research Programs/Design for This Report
  • Table 518. Key Data Information from Secondary Sources
  • Table 519. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gout Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Gout Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Gout Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Gout Drugs: by Disease Condition USD Million (2018-2023)
  • Figure 8. South America Gout Drugs Share (%), by Country
  • Figure 9. Asia Pacific Gout Drugs Share (%), by Country
  • Figure 10. Europe Gout Drugs Share (%), by Country
  • Figure 11. MEA Gout Drugs Share (%), by Country
  • Figure 12. North America Gout Drugs Share (%), by Country
  • Figure 13. Global Gout Drugs: by Type Unit (2018-2023)
  • Figure 14. Global Gout Drugs: by Application Unit (2018-2023)
  • Figure 15. Global Gout Drugs: by Distribution Channel Unit (2018-2023)
  • Figure 16. Global Gout Drugs: by Disease Condition Unit (2018-2023)
  • Figure 17. South America Gout Drugs Share (%), by Country
  • Figure 18. Asia Pacific Gout Drugs Share (%), by Country
  • Figure 19. Europe Gout Drugs Share (%), by Country
  • Figure 20. MEA Gout Drugs Share (%), by Country
  • Figure 21. North America Gout Drugs Share (%), by Country
  • Figure 22. Global Gout Drugs: by Type USD/Units (2018-2023)
  • Figure 23. Global Gout Drugs share by Players 2023 (%)
  • Figure 24. Global Gout Drugs share by Players (Top 3) 2023(%)
  • Figure 25. Global Gout Drugs share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Sun Pharma (India) Revenue, Net Income and Gross profit
  • Figure 28. Sun Pharma (India) Revenue: by Geography 2023
  • Figure 29. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 30. Mylan (United States) Revenue: by Geography 2023
  • Figure 31. Apotex (Canda) Revenue, Net Income and Gross profit
  • Figure 32. Apotex (Canda) Revenue: by Geography 2023
  • Figure 33. Synpac-Kingdom (Taiwan) Revenue, Net Income and Gross profit
  • Figure 34. Synpac-Kingdom (Taiwan) Revenue: by Geography 2023
  • Figure 35. Yunnan Phytopharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 36. Yunnan Phytopharmaceutical (China) Revenue: by Geography 2023
  • Figure 37. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 39. Horizon Pharma plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 40. Horizon Pharma plc (Ireland) Revenue: by Geography 2023
  • Figure 41. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 42. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2023
  • Figure 43. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 44. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 45. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 46. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 47. Global Gout Drugs: by Type USD Million (2024-2029)
  • Figure 48. Global Gout Drugs: by Application USD Million (2024-2029)
  • Figure 49. Global Gout Drugs: by Distribution Channel USD Million (2024-2029)
  • Figure 50. Global Gout Drugs: by Disease Condition USD Million (2024-2029)
  • Figure 51. South America Gout Drugs Share (%), by Country
  • Figure 52. Asia Pacific Gout Drugs Share (%), by Country
  • Figure 53. Europe Gout Drugs Share (%), by Country
  • Figure 54. MEA Gout Drugs Share (%), by Country
  • Figure 55. North America Gout Drugs Share (%), by Country
  • Figure 56. Global Gout Drugs: by Type Unit (2024-2029)
  • Figure 57. Global Gout Drugs: by Application Unit (2024-2029)
  • Figure 58. Global Gout Drugs: by Distribution Channel Unit (2024-2029)
  • Figure 59. Global Gout Drugs: by Disease Condition Unit (2024-2029)
  • Figure 60. South America Gout Drugs Share (%), by Country
  • Figure 61. Asia Pacific Gout Drugs Share (%), by Country
  • Figure 62. Europe Gout Drugs Share (%), by Country
  • Figure 63. MEA Gout Drugs Share (%), by Country
  • Figure 64. North America Gout Drugs Share (%), by Country
  • Figure 65. Global Gout Drugs: by Type USD/Units (2024-2029)
List of companies from research coverage that are profiled in the study
  • Sun Pharma (India)
  • Mylan (United States)
  • Apotex (Canda)
  • Synpac-Kingdom (Taiwan)
  • Yunnan Phytopharmaceutical (China)
  • AstraZeneca (United Kingdom)
  • Horizon Pharma plc (Ireland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • GlaxoSmithKline plc (United Kingdom)
  • Novartis AG (Switzerland)
Additional players considered in the study are as follows:
Merck & Co. Inc. (United States) , Teijin Pharma Limited (Japan)
Select User Access Type

Key Highlights of Report


Jan 2024 221 Pages 96 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gout Drugs research Quantitative research analysis
Global Gout Drugs research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Gout Drugs market is predicted to grow at a CAGR of % between 2023 - 2029.
Global Gout Drugs market is restrained by Strict Regulations of Various Drugs may Hinder the Gout Drug Market and Concern Related Towards the Patent Expiry of these Drugs.
The Gout Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.

Know More About Global Gout Drugs research Report?

Have a Query? Click Here

Other Related Reports

Varicose veins treatment Comprehensive Study by Treatment (Surgery, Ligation and Stripping, Sclerotherapy, Radiofrequency Ablation, Endovenous Laser Treatment, Transilluminated Powered Phlebectomy), ...
$ 3750
Basal Cell Nevus Syndrome Drug Comprehensive Study by Type (Itraconazole, Patidegib Hydrochloride, REM-001, TG-1042, Trifarotene, Others), Application (Clinic, Hospital, Others), Drugs (Aldara (Imiqu...
$ 3650
Autoimmune Disease Diagnosis Comprehensive Study by Type (Rheumatoid arthritis, Lupus, Coeliac disease, Type 1 diabetes, Others), End Users (Hospitals, Clinics, Pharmaceutical Companies, Government R...
$ 3750
Mycoplasma Testing Comprehensive Study by Type (Instruments, Kits & Reagents (Elimination Kits & Reagent, Standards & Controls, PCR Assay, Stains, Nucleic Acid Detection, Other), Services), Applicati...
$ 3750
Bracing and Supports Comprehensive Study by Type (Knee Braces & Supports, Foot and Ankle Braces & Supports, Spinal Orthoses, Upper Extremity Braces & Supports), Application (Ligament Injury, Preventi...
$ 3650
Endodontics Treatments Comprehensive Study by Type (Root Canal Therapy, Fixing Broken Teeth, Dental Trauma), Application (Hospitals, Dental Clinic, Laboratories, Dental Academic Research Institute), ...
$ 3750